annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 5 The impact of body mass index (BMI) and body surface area (BSA) on
treatment outcome to vascular endothelial growth factor (VEGF)-targeted
therapy in metastatic renal cell carcinoma: Results from a large international
collaboration. (Abstract #4524)
T. K. Choueiri, W. Xie, C. K. Kollmannsberger, B. I. Rini, D. F. McDermott,
J. J. Knox, D. Y. Heng
Brd. 6 Use of progression-free survival (PFS) to predict overall survival (OS) in
patients with metastatic renal cell carcinoma (mRCC). (Abstract #4525)
S. Halabi, B. I. Rini, W. M. Stadler, E. J. Small
Brd. 7 Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage,
radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in
advanced renal cell carcinoma. (Abstract #4526)
K. M. Krajewski, D. Y. Heng, I. Pedrosa, N. H. Ramaiya, J. P. Jagannathan,
A. D. Van Den Abbeele, M. B. Atkins, D. F. McDermott, F. A. Schutz, T. K. Choueiri
Brd. 8 Phase II trial of linifanib in patients with advanced renal cell cancer (RCC)
after sunitinib failure. (Abstract #4527)
N. M. Tannir, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry,
L. J. Appleman, E. M. Posadas, J. Qian, J. L. Ricker, D. Michaelson
Brd. 9 A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal
carcinoma (RCC). (Abstract #4528^)
C. W. Ryan, B. D. Curti, D. I. Quinn, J. M. Strother, Z. Chen, E. Roberson,
T. M. Beer, D. Nauman
Brd. 10 Results of a randomized phase II study investigating multipeptide
vaccination with IMA901 in advanced renal cell carcinoma (RCC). (Abstract
#4529)
C. Reinhardt, R. Zdrojowy, C. Szczylik, T. Ciuleanu, W. Brugger, R. Oberneder,
A. Kirner, S. Walter, H. Singh, A. Stenzl
Brd. 12 Results from SWENOTECA V: A population-based protocol for
seminomatous testicular cancer. (Abstract #4531)
T. Tandstad, R. Småland, O. H. Klepp, E. Cavallin-Stahl, U. Stierner, A. Laurell,
P. Flodgren, O. Dahl, G. Cohn-Cedermark
Brd. 13 Risk-adapted management of stage I seminoma: Results of the third Spanish
Germ Cell Cancer Group study. (Abstract #4532)
J. Aparicio, L. Robert, X. Garcia del Muro, J. Guma, A. Sanchez, M. Margeli,
M. Domenech, R. Bastus, J. P. Maroto, J. R. Germa-Lluch, Spanish Germ Cell
Cancer Group
Brd. 14 Cardiovascular risk in long-term testicular cancer survivors. (Abstract #4533)
H. S. Haugnes, T. Wethal, N. Aass, O. Dahl, O. H. Klepp, C. Langberg, T.
Wilsgaard, R. M. Bremnes, S. D. Fossa
Brd. 15 Total treatment burden in stage I seminoma patients. (Abstract #4534)
E. Leung, P. W. Chung, T. Panzarella, M. A. Jewett, J. Sweet, M. O’Malley,
M. K. Gospodarowicz, M. J. Moore, J. F. Sturgeon, P. R. Warde
Brd. 16 Prognostic factors for relapse in stage I seminoma managed with
surveillance: A validation study. (Abstract #4535)
P. W. Chung, G. Daugaard, S. Tyldesley, T. Panzarella, C. K. Kollmannsberger,
M. K. Gospodarowicz, P. R. Warde
Brd. 17 Evolution of management of testicular seminoma: Population-based
outcomes with decreased utilization of active therapies. (Abstract #4536)
C. R. Nichols, S. Tyldesley, C. J. Moore, K. N. Chi, N. Murray, S. Daneshmand,
P. C. Black, B. M. Hayes-Lattin, C. K. Kollmannsberger
Brd. 18 Risk of secondary malignancy in patients with testicular cancer who have
received radiation therapy. (Abstract #4537)
D. Lewinshtein, C. R. Porter
Brd. 19 Risk of second cancers among a cohort of 2,703 long-term survivors of
testicular seminoma treated with radiotherapy. (Abstract #4538)
A. Horwich, S. D. Fossa, S. P. Stenning, J. M. Bliss, E. Hall
141
SATURDAY